Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-11-07
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 180000 NOK
Award criteria: Lowest price

Technical requirements: Voluntary ex ante transparency notice - Additional agreement for LIS 2301d lidocaine injection, sterile ampoule without preservation, ATC code N01BB02
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for Parenteral special pharmaceutical preparations (LIS 2301d). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
No agreements were signed for the delivery of Lidocaine injection, sterile ampoule without preservation, ATC code N01BB02. We still need to enter into an agreement.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for Parenteral special pharmaceutical preparations (LIS 2301d). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
No agreements were signed for the delivery of Lidocaine injection, sterile ampoule without preservation, ATC code N01BB02. We still need to enter into an agreement.
Due to this, LIS intends to enter into agreements between the regional health authorities (the Contracting Authorities) and Aspen Pharma (the Supplier) as an additional contract to LIS 2301d. I.e. the scope and length of the agreement must be in accordance with the mentioned procurement (including access to extensions and terminations), without a new competition being held for this active ingredient. The health trusts that are under the regional health authorities have options for enter the agreements. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has explored the market situation and is of the opinion that it is impossible to carry out a new invitation to tender, or that a supplier other than Aspen Pharma can deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authorities' fault, nor something that the contracting authorities could predict. LIS therefore believes that there are grounds to carry out the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this contract award are submitted before the expiry of the waiting period, set to 10 days after the publication of the Voluntary ex ante transparency notice. If no objections are received, contracts will be signed after the waiting period has expired.
LIS has explored the market situation and is of the opinion that it is impossible to carry out a new invitation to tender, or that a supplier other than Aspen Pharma can deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authorities' fault, nor something that the contracting authorities could predict. LIS therefore believes that there are grounds to carry out the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.


Winner: Aspen Pharma Ireland Limited
Award value: 180000